This site is intended for U.S. residents only. For Novartis Worldwide, Click here

Mailing List


	Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only.

Study Description

Screening

Study Centers

Contact/Consent

Lung Cancer

Cancers that begin in the lungs are divided into two major types, non-small cell lung cancer and small cell lung cancer, depending on how the cells look under a microscope. Non-small cell lung cancer is more common than small cell lung cancer, and it generally grows and spreads more slowly. Small cell lung cancer, sometimes called oat cell cancer, is less common, grows more quickly and is more likely to spread to other organs in the body. [Source: www.nihseniorhealth.gov]

Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial.

How to use this system:

The purpose of this system is to help connect interested study participants with clinical research centers. The following is a brief outline explaining the main steps involved in using this system. Please note that every step in this process is optional.

1. Select a clinical trial that you feel best suits your (or the      participant's) health condition.
2. Answer the screening questions to see if you (or the      participant) meet the preliminary qualifications for the study.      The answers to these questions are not retained by this      system.
3. Select a study center to contact for additional information      about the clinical trial.
4. Set up an account and agree to the terms of use for this      system.
5. Submit your information to the study center you selected.
6. The study center may contact you and may ask more      questions about your (or the participant's) eligibility for the      study. The study center may invite you (and the participant if      applicable) to travel to the study center for additional screening      tests. Novartis cannot guarantee that you will be contacted by      the study center.
7. If you are eligible to participate in the study, then you will be      required to sign an informed consent before enrolling in the      study. An informed consent is provided to you to help you      understand the clinical trial, the nature of the medical treatment      (if any), procedures and known risks involved, before you agree      to participate in the study.

For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy.

Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.

Brain Metastases from Lung Cancer Study CEPO906A2227

Novartis Oncology is conducting a clinical research study to find out if the study drug, patupilone, is an effective and safe treatment for people who are 18 years or older and have non-small cell lung cancer that has spread to the brain, and that is recurrent in the brain after treatment. The research study is an open-label study, which means that everyone participating in the study will receive the study drug patupilone once every 3 weeks. Patupilone is given by intravenous infusion (directly into a vein) lasting approximately 20 minutes. Patients may remain in the study as long as they and the study doctor think it is in their best interest to participate. The study drug, patupilone, is an investigational drug which has not been approved by the FDA (US Food and Drug Administration) or the EMEA (European Medicines Agency) for the treatment of people with your medical condition.
Trial phase: Phase 2
Participation Duration: Study site visits approx. 2 times a month. The first visits at cycles 1 and 3 may require overnight stays. A final study visit must be performed 28 days after last administration of study drug for all patients regardless of reason for discontinuation.
Protocol Number: CEPO906A2227

Advanced Non-small Cell Lung Cancer Study CASA404A2301

The purpose of this study is to determine if adding the study drug ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with newly diagnosed advanced non-small cell lung cancer. The standard chemotherapy regimen that all patients receive in this study is paclitaxel plus carboplatin. Participants will also receive either ASA404 or a placebo (half will receive ASA404, half will receive placebo). The study drug ASA404 is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).
Trial phase: Phase 3
Participation Duration: Participants will receive a maximum of 6 cycles of study treatment. Each treatment cycle is 21 days (3 weeks) long. Participants will return to their doctor’s office every 3 weeks so that their condition can be monitored. The number of treatment cycles for each participant depends on how they respond to treatment and whether they suffer from any side effects.
Protocol Number: CASA404A2301

	Site Map \| Contact Us \| Clinical Trial Search \| Mailing List \| Clinical Trial FAQs
	Participation FAQs \| Clinical Trials Glossary \| About Informed Consent
	Novartis Medical and Clinical Research

Clinical Trial Search

Lung Cancer